Skip to content
Anthem Biosciences logo

Anthem Biosciences IPO

MainboardListedPharma & Healthcare
Check allotment status
Issue price
₹570
Listing price
₹723.05
+26.85%
Current price
₹936.95
+64.38%
Subscribed
67.42x
Issue size
₹3,395 Cr
Listed on
21 Jul 2025

IPO timeline

  1. Opens
    14 JulMon
  2. Closes
    16 JulWed
  3. Allotment
    17 JulThu
  4. Refunds
    18 JulFri
  5. Demat credit
    18 JulFri
  6. Listing
    21 JulMon

Issue details

Price band
₹540 – ₹570 per share
Issue size
₹3,395 Cr
Fresh issue
None
Offer for sale
₹3,395 Cr
Issue type
OFS only
Face value
₹2 per share
Lot size
26 shares
Minimum investment
₹14,820
Listing on
BSE, NSE
Exchange code
ANTHEM · 544449

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)126₹14,820
Retail (Max)13338₹1,92,660
S-HNI (Min)14364₹2,07,480
B-HNI (Min)681,768₹10,07,760

Reservation

QIB
2,97,08,332 shares (50.00% of the Offer)
NII
89,12,500 shares (15.00% of the Offer)
Retail
2,07,95,834 shares (35.00% of the Offer)
Employee
1,58,653 shares (0.27% of the Offer)

Allotment status

Registrar: KFin Technologies Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on KFin Technologies
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
17 Jul 2025
Refunds initiated
18 Jul 2025
Shares credited to demat
18 Jul 2025
Listing
21 Jul 2025
Basis of allotment document

Grey market premium (GMP)

Updated 21 Jul 2025, 12:00 PM IST
Current GMP
₹170
+30.00%
Estimated listing price
₹740
Issue price ₹570
Highest
₹170
21 Jul
Lowest
₹60
8 Jul

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
21 Jul 2025₹170+30.00%₹740
20 Jul 2025₹167+29.00%₹737
19 Jul 2025₹156+27.00%₹726
18 Jul 2025₹133+23.00%₹703
17 Jul 2025₹140+25.00%₹710
16 Jul 2025₹148+26.00%₹718
15 Jul 2025₹141+25.00%₹711
14 Jul 2025₹110+19.00%₹680
12 Jul 2025₹98+17.00%₹668
11 Jul 2025₹94+16.00%₹664
10 Jul 2025₹106+19.00%₹676
9 Jul 2025₹90+16.00%₹660
8 Jul 2025₹60+11.00%₹630
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 09 Nov 2026, 08:48 PM IST
Overall subscription
67.42x
Fully subscribed · 36,33,975 applications
  • QIB192.8x
  • NII (HNI)44.7x
  • Retail5.98x
  • Employee6.99x

Financials

Amounts in Rs. Crore
P/E (pre-issue)
70.62
P/E (post-issue)
70.62
EPS (₹)
8.07
RoE
20.82%
RoCE
26.88%
RoNW
20.82%
PAT Margin
23.38%
EBITDA Margin
36.81%
Debt / Equity
0.05
NAV (₹)
43.10

Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price.

Period ended31 Mar 202531 Mar 202431 Mar 2023
Assets2,807.582,398.112,014.46
Total Income1,930.291,483.071,133.99
Profit After Tax451.26367.31385.19
EBITDA683.78519.96446.05
NET Worth2,409.861,924.661,740.67
Reserves and Surplus2,298.051,815.391,628.88
Total Borrowing108.95232.53125.06
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Anthem Biosciences
This IPO
₹3,395 Cr70.6220.82%23.38%67.42x+26.85%
Sai Life Sciences
Mainboard · listed 18 Dec 2024
₹3,042.62 Cr203.828.13%5.65%10.27x+18.40%
Inventurus Knowledge Solutions
Mainboard · listed 19 Dec 2024
₹2,497.92 Cr54.6632%20.38%52.68x+42.96%
Sagility India
Mainboard · listed 12 Nov 2024
₹2,106.4 Cr61.520.29%11.83%3.2x+3.53%
Akums Drugs & Pharmaceuticals
Mainboard · listed 6 Aug 2024
₹1,856.74 Cr13580-0.57%0.02%63.44x+6.77%
Indegene
Mainboard · listed 13 May 2024
₹1,841.76 Cr33.5318.23%12.62%70.3x+44.91%
Symbiotec Pharmalab
Mainboard · listed 1 Sep 2026
₹1,757 Cr56.819.48%12.60%71.26x0.00%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

About Anthem Biosciences

Anthem Biosciences Limited was incorporated in 2006. It is a contract research, development and manufacturing organisation. Its operations cover drug discovery, development and manufacturing for emerging biotech firms and large pharmaceutical companies. The company also makes fermentation-based active ingredients. These include probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. On 30 September 2024 it had 196 projects. In the six months to that date it made active ingredients and intermediates for ten commercial molecules, all supported since discovery. The IPO was entirely an offer for sale of Rs 3,395 crore, so the company received no money from it.

Strengths

  • Total income rose from Rs 1,133.99 crore in FY2023 to Rs 1,930.29 crore in FY2025.
  • The EBITDA margin was 36.81% and the PAT margin was 23.38%.
  • Total borrowing fell from Rs 232.53 crore on 31 March 2024 to Rs 108.95 crore on 31 March 2025.
  • Return on equity was 20.82% and return on capital employed was 26.88%.
  • The company had 196 projects on 30 September 2024.

Risks

  • The whole Rs 3,395 crore issue was offer for sale. The company got no fresh money.
  • The P/E was 70.62 at the upper band of Rs 570, based on EPS of Rs 8.07.
  • Profit after tax fell from Rs 385.19 crore in FY2023 to Rs 367.31 crore in FY2024 before rising in FY2025.
  • Contract manufacturing income can be lumpy, and the company made ingredients for only 10 commercial molecules in the six months to 30 September 2024.
  • Promoters held 76.87% before the issue and held 74.68% after it.
  • Most customers are drug developers, so funding cycles in biotech can reduce the Rs 1,930.29 crore income base.

Promoters and shareholding

Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj

Promoter holding, pre-issue
76.87%
Promoter holding, post-issue
74.68%

Registrar, lead managers and documents

Anthem Biosciences IPO: common questions

1.When does the Anthem Biosciences IPO open and close?

The Anthem Biosciences IPO opens on 14 Jul 2025 and closes on 16 Jul 2025.

2.What is the price band of the Anthem Biosciences IPO?

The price band is ₹540 – ₹570 per share, with a lot size of 26 shares and a minimum investment of ₹14,820.

3.What is the size of the Anthem Biosciences IPO?

The issue size is ₹3,395 Cr (OFS only).

4.What is the GMP of the Anthem Biosciences IPO?

The last reported grey market premium is ₹170 per share as of 21 Jul 2025, 12:00 PM IST. GMP is unofficial and changes frequently.

5.When is the Anthem Biosciences IPO allotment?

The basis of allotment is expected on 17 Jul 2025. Allotment status can be checked with the registrar, KFin Technologies Limited.

6.When will the Anthem Biosciences IPO list?

The shares listed on 21 Jul 2025 on BSE, NSE.

7.Who is the lead manager of the Anthem Biosciences IPO?

The book running lead managers are JM Financial Ltd., JP Morgan India Pvt. Ltd, Citigroup Global Markets India Pvt. Ltd, Nomura Financial Advisory & Securities (India) Pvt. Ltd, and the registrar is KFin Technologies Limited.

8.How can my company launch an IPO like Anthem Biosciences?

Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393